Review



cd19 car detection reagent  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Miltenyi Biotec cd19 car detection reagent
    Generation of CAR19-NK-92 and CAR19-GITRL-NK-92 cells. (A) SFFV-driven CAR19 and CAR19-GITRL constructs: FMC63 <t>anti-CD19</t> scFv linked to CD28 transmembrane and CD28/CD3ζ signaling domains; CAR19-GITRL includes a P2A sequence followed by GITRL, whereas CAR19 contains a stop codon. (B) NK-92 cells were transduced with VSV-G–pseudotyped lentiviral particles (MOI 10) in the presence of polybrene (8 μg/mL) and BX795 (16 μM); CAR expression was assessed by flow cytometry. (C) CAR-positive cells were enriched by FACS (FACSAria Fusion), and CAR, GITR, and GITRL expression were quantified by flow cytometry.
    Cd19 Car Detection Reagent, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 122 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd19/CD19+CAR+Detection+Reagent%2C+human/pmc13389840-46-5-9
    Average 96 stars, based on 122 article reviews
    cd19 car detection reagent - by Bioz Stars, 2026-11
    96/100 stars

    Images

    1) Product Images from "Coexpression of GITRL confers resistance to Treg cell-mediated immunosuppression to anti-CD19 CAR-NK cells"

    Article Title: Coexpression of GITRL confers resistance to Treg cell-mediated immunosuppression to anti-CD19 CAR-NK cells

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2026.1818610

    Generation of CAR19-NK-92 and CAR19-GITRL-NK-92 cells. (A) SFFV-driven CAR19 and CAR19-GITRL constructs: FMC63 anti-CD19 scFv linked to CD28 transmembrane and CD28/CD3ζ signaling domains; CAR19-GITRL includes a P2A sequence followed by GITRL, whereas CAR19 contains a stop codon. (B) NK-92 cells were transduced with VSV-G–pseudotyped lentiviral particles (MOI 10) in the presence of polybrene (8 μg/mL) and BX795 (16 μM); CAR expression was assessed by flow cytometry. (C) CAR-positive cells were enriched by FACS (FACSAria Fusion), and CAR, GITR, and GITRL expression were quantified by flow cytometry.
    Figure Legend Snippet: Generation of CAR19-NK-92 and CAR19-GITRL-NK-92 cells. (A) SFFV-driven CAR19 and CAR19-GITRL constructs: FMC63 anti-CD19 scFv linked to CD28 transmembrane and CD28/CD3ζ signaling domains; CAR19-GITRL includes a P2A sequence followed by GITRL, whereas CAR19 contains a stop codon. (B) NK-92 cells were transduced with VSV-G–pseudotyped lentiviral particles (MOI 10) in the presence of polybrene (8 μg/mL) and BX795 (16 μM); CAR expression was assessed by flow cytometry. (C) CAR-positive cells were enriched by FACS (FACSAria Fusion), and CAR, GITR, and GITRL expression were quantified by flow cytometry.

    Techniques Used: Construct, Sequencing, Transduction, Expressing, Flow Cytometry

    Related Articles

    Recombinant:

    Article Title: A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug products
    Article Snippet: .. Dynabeads M-280 Streptavidin (Invitrogen, Thermo Scientific, Waltham, MA, USA) were loaded with CD19 CAR Detection Reagent, human, Biotin (Miltenyi Biotec), Biotinylated Recombinant Human CD7 (carrier-free) (Biolegend, California, USA), Recombinant human ErbB2/HER2 (biotinylated) protein (Abcam, Cambridge, UK) or incubated with 1× phosphate buffered saline (PBS) as a non-loaded control. .. Beads were counted using a MacsQuant Analyzer 10 (Miltenyi Biotec) and 500 × 10 3 were washed and resuspended in PBS.

    Biotinylation:

    Article Title: A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug products
    Article Snippet: .. Dynabeads M-280 Streptavidin (Invitrogen, Thermo Scientific, Waltham, MA, USA) were loaded with CD19 CAR Detection Reagent, human, Biotin (Miltenyi Biotec), Biotinylated Recombinant Human CD7 (carrier-free) (Biolegend, California, USA), Recombinant human ErbB2/HER2 (biotinylated) protein (Abcam, Cambridge, UK) or incubated with 1× phosphate buffered saline (PBS) as a non-loaded control. .. Beads were counted using a MacsQuant Analyzer 10 (Miltenyi Biotec) and 500 × 10 3 were washed and resuspended in PBS.

    Incubation:

    Article Title: A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug products
    Article Snippet: .. Dynabeads M-280 Streptavidin (Invitrogen, Thermo Scientific, Waltham, MA, USA) were loaded with CD19 CAR Detection Reagent, human, Biotin (Miltenyi Biotec), Biotinylated Recombinant Human CD7 (carrier-free) (Biolegend, California, USA), Recombinant human ErbB2/HER2 (biotinylated) protein (Abcam, Cambridge, UK) or incubated with 1× phosphate buffered saline (PBS) as a non-loaded control. .. Beads were counted using a MacsQuant Analyzer 10 (Miltenyi Biotec) and 500 × 10 3 were washed and resuspended in PBS.

    Article Title: Development of Replicon Cell Pools Bearing a Flavivirus RNA Replicon as a Source of HIV-1 Gag-Pol for Lentiviral Vector Production.
    Article Snippet: Cells were detached with trypsin-EDTA, washed with PBS, and resuspended in 1 mL of MACSQuant Running Buffer for cytometry (RB, Miltenyi Biotec Cat. 130-092-747). .. For the LV/CAR vector, non-permeabilized cells were stained by sequential incubation with biotinylated CD19 CAR Detection Reagent (Miltenyi Biotec Cat. 130-129-550) and anti-biotin-PE antibody (Miltenyi Biotec Cat. 130-113-291). .. Samples were acquired on a MACSQuant 10 flow cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany).

    Saline:

    Article Title: A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug products
    Article Snippet: .. Dynabeads M-280 Streptavidin (Invitrogen, Thermo Scientific, Waltham, MA, USA) were loaded with CD19 CAR Detection Reagent, human, Biotin (Miltenyi Biotec), Biotinylated Recombinant Human CD7 (carrier-free) (Biolegend, California, USA), Recombinant human ErbB2/HER2 (biotinylated) protein (Abcam, Cambridge, UK) or incubated with 1× phosphate buffered saline (PBS) as a non-loaded control. .. Beads were counted using a MacsQuant Analyzer 10 (Miltenyi Biotec) and 500 × 10 3 were washed and resuspended in PBS.

    Control:

    Article Title: A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug products
    Article Snippet: .. Dynabeads M-280 Streptavidin (Invitrogen, Thermo Scientific, Waltham, MA, USA) were loaded with CD19 CAR Detection Reagent, human, Biotin (Miltenyi Biotec), Biotinylated Recombinant Human CD7 (carrier-free) (Biolegend, California, USA), Recombinant human ErbB2/HER2 (biotinylated) protein (Abcam, Cambridge, UK) or incubated with 1× phosphate buffered saline (PBS) as a non-loaded control. .. Beads were counted using a MacsQuant Analyzer 10 (Miltenyi Biotec) and 500 × 10 3 were washed and resuspended in PBS.

    FACS:

    Article Title: Safe Redosable Low-Immunogenic In Vivo CAR-T Therapy for B Cell Malignancies and Solid Tumors
    Article Snippet: .. Cells were analyzed on BD FACS Aria, Accuri, Lyric, or Beckman Coulter CytoFLEX instruments and data analyzed using FlowJo v10 or CytExpert software as described previously., CAR transgene expression was detected using CAR-specific detection reagents: CD19 CAR detection (Miltenyi Biotec #130-129-550), BCMA CAR detection (Miltenyi Biotec #130-126-727), anti-4-1BB monoclonal antibodies for 4-1BB-containing constructs, anti-G4S linker antibody for GPRC5D (#62405, Cell Signaling Technologies) and CLDN18.2 CARs, or Protein L-APC (CST #29480) for CD20 CAR. .. T cell immunophenotyping used fluorophore-conjugated antibodies against CD3, CD4, CD8, CD27, CCR7, CD45RA, and CD62L to identify memory subsets and exhaustion markers, and off-target markers CD45, CD19, CD20, CD14, CD15, CD56 were assessed, as mentioned previously., Intracellular staining for Granzyme B (clone GB11, BioLegend) and phospho-STAT5 (Tyr694; Cat no. 12901042, Thermo Fisher) was performed after fixation/permeabilization (Intracellular Fixation and Permeabilization Buffer Set, Cat no. 88882400, Thermo Fisher).

    Article Title: Engineered mRNA backbones for gene expression in human T cells
    Article Snippet: .. Cells were harvested 24–48 h post-electroporation, washed in FACS buffer (PBS with 2% FBS), and stained with the following fluorochrome-conjugated antibodies: CD19 CAR Detection Reagent, Biotin (Miltenyi Biotec, #130-129-550), followed by secondary staining with Anti-Biotin-APC (Miltenyi Biotec, REAfinity #130-113-854); TIM-3 APC-Cy7 (BioLegend, #345025); 4-1BB PE-Cy7 (BioLegend, #309820); Viability Dye eFluor 506/AmCyan (Thermo Fisher Scientific, #65-0866-14). ..

    Software:

    Article Title: Safe Redosable Low-Immunogenic In Vivo CAR-T Therapy for B Cell Malignancies and Solid Tumors
    Article Snippet: .. Cells were analyzed on BD FACS Aria, Accuri, Lyric, or Beckman Coulter CytoFLEX instruments and data analyzed using FlowJo v10 or CytExpert software as described previously., CAR transgene expression was detected using CAR-specific detection reagents: CD19 CAR detection (Miltenyi Biotec #130-129-550), BCMA CAR detection (Miltenyi Biotec #130-126-727), anti-4-1BB monoclonal antibodies for 4-1BB-containing constructs, anti-G4S linker antibody for GPRC5D (#62405, Cell Signaling Technologies) and CLDN18.2 CARs, or Protein L-APC (CST #29480) for CD20 CAR. .. T cell immunophenotyping used fluorophore-conjugated antibodies against CD3, CD4, CD8, CD27, CCR7, CD45RA, and CD62L to identify memory subsets and exhaustion markers, and off-target markers CD45, CD19, CD20, CD14, CD15, CD56 were assessed, as mentioned previously., Intracellular staining for Granzyme B (clone GB11, BioLegend) and phospho-STAT5 (Tyr694; Cat no. 12901042, Thermo Fisher) was performed after fixation/permeabilization (Intracellular Fixation and Permeabilization Buffer Set, Cat no. 88882400, Thermo Fisher).

    Expressing:

    Article Title: Safe Redosable Low-Immunogenic In Vivo CAR-T Therapy for B Cell Malignancies and Solid Tumors
    Article Snippet: .. Cells were analyzed on BD FACS Aria, Accuri, Lyric, or Beckman Coulter CytoFLEX instruments and data analyzed using FlowJo v10 or CytExpert software as described previously., CAR transgene expression was detected using CAR-specific detection reagents: CD19 CAR detection (Miltenyi Biotec #130-129-550), BCMA CAR detection (Miltenyi Biotec #130-126-727), anti-4-1BB monoclonal antibodies for 4-1BB-containing constructs, anti-G4S linker antibody for GPRC5D (#62405, Cell Signaling Technologies) and CLDN18.2 CARs, or Protein L-APC (CST #29480) for CD20 CAR. .. T cell immunophenotyping used fluorophore-conjugated antibodies against CD3, CD4, CD8, CD27, CCR7, CD45RA, and CD62L to identify memory subsets and exhaustion markers, and off-target markers CD45, CD19, CD20, CD14, CD15, CD56 were assessed, as mentioned previously., Intracellular staining for Granzyme B (clone GB11, BioLegend) and phospho-STAT5 (Tyr694; Cat no. 12901042, Thermo Fisher) was performed after fixation/permeabilization (Intracellular Fixation and Permeabilization Buffer Set, Cat no. 88882400, Thermo Fisher).

    Bioprocessing:

    Article Title: Safe Redosable Low-Immunogenic In Vivo CAR-T Therapy for B Cell Malignancies and Solid Tumors
    Article Snippet: .. Cells were analyzed on BD FACS Aria, Accuri, Lyric, or Beckman Coulter CytoFLEX instruments and data analyzed using FlowJo v10 or CytExpert software as described previously., CAR transgene expression was detected using CAR-specific detection reagents: CD19 CAR detection (Miltenyi Biotec #130-129-550), BCMA CAR detection (Miltenyi Biotec #130-126-727), anti-4-1BB monoclonal antibodies for 4-1BB-containing constructs, anti-G4S linker antibody for GPRC5D (#62405, Cell Signaling Technologies) and CLDN18.2 CARs, or Protein L-APC (CST #29480) for CD20 CAR. .. T cell immunophenotyping used fluorophore-conjugated antibodies against CD3, CD4, CD8, CD27, CCR7, CD45RA, and CD62L to identify memory subsets and exhaustion markers, and off-target markers CD45, CD19, CD20, CD14, CD15, CD56 were assessed, as mentioned previously., Intracellular staining for Granzyme B (clone GB11, BioLegend) and phospho-STAT5 (Tyr694; Cat no. 12901042, Thermo Fisher) was performed after fixation/permeabilization (Intracellular Fixation and Permeabilization Buffer Set, Cat no. 88882400, Thermo Fisher).

    Construct:

    Article Title: Safe Redosable Low-Immunogenic In Vivo CAR-T Therapy for B Cell Malignancies and Solid Tumors
    Article Snippet: .. Cells were analyzed on BD FACS Aria, Accuri, Lyric, or Beckman Coulter CytoFLEX instruments and data analyzed using FlowJo v10 or CytExpert software as described previously., CAR transgene expression was detected using CAR-specific detection reagents: CD19 CAR detection (Miltenyi Biotec #130-129-550), BCMA CAR detection (Miltenyi Biotec #130-126-727), anti-4-1BB monoclonal antibodies for 4-1BB-containing constructs, anti-G4S linker antibody for GPRC5D (#62405, Cell Signaling Technologies) and CLDN18.2 CARs, or Protein L-APC (CST #29480) for CD20 CAR. .. T cell immunophenotyping used fluorophore-conjugated antibodies against CD3, CD4, CD8, CD27, CCR7, CD45RA, and CD62L to identify memory subsets and exhaustion markers, and off-target markers CD45, CD19, CD20, CD14, CD15, CD56 were assessed, as mentioned previously., Intracellular staining for Granzyme B (clone GB11, BioLegend) and phospho-STAT5 (Tyr694; Cat no. 12901042, Thermo Fisher) was performed after fixation/permeabilization (Intracellular Fixation and Permeabilization Buffer Set, Cat no. 88882400, Thermo Fisher).

    Staining:

    Article Title: Engineered mRNA backbones for gene expression in human T cells
    Article Snippet: .. Cells were harvested 24–48 h post-electroporation, washed in FACS buffer (PBS with 2% FBS), and stained with the following fluorochrome-conjugated antibodies: CD19 CAR Detection Reagent, Biotin (Miltenyi Biotec, #130-129-550), followed by secondary staining with Anti-Biotin-APC (Miltenyi Biotec, REAfinity #130-113-854); TIM-3 APC-Cy7 (BioLegend, #345025); 4-1BB PE-Cy7 (BioLegend, #309820); Viability Dye eFluor 506/AmCyan (Thermo Fisher Scientific, #65-0866-14). ..

    Article Title: Coexpression of GITRL confers resistance to Treg cell-mediated immunosuppression to anti-CD19 CAR-NK cells
    Article Snippet: .. CAR-positive cells were stained with CD19 CAR detection reagent (Miltenyi Biotec) for 10 minutes followed by Biotin-PE or Biotin-APC secondary antibodies (Miltenyi Biotec) staining during 15 minutes and analysis with FACSymphony A1 (BD Biosciences). .. Sorting of CAR-positive cells was performed with FACSAria Fusion (BD Biosciences).

    Article Title: Development of Replicon Cell Pools Bearing a Flavivirus RNA Replicon as a Source of HIV-1 Gag-Pol for Lentiviral Vector Production.
    Article Snippet: Cells were detached with trypsin-EDTA, washed with PBS, and resuspended in 1 mL of MACSQuant Running Buffer for cytometry (RB, Miltenyi Biotec Cat. 130-092-747). .. For the LV/CAR vector, non-permeabilized cells were stained by sequential incubation with biotinylated CD19 CAR Detection Reagent (Miltenyi Biotec Cat. 130-129-550) and anti-biotin-PE antibody (Miltenyi Biotec Cat. 130-113-291). .. Samples were acquired on a MACSQuant 10 flow cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany).

    Plasmid Preparation:

    Article Title: Development of Replicon Cell Pools Bearing a Flavivirus RNA Replicon as a Source of HIV-1 Gag-Pol for Lentiviral Vector Production.
    Article Snippet: Cells were detached with trypsin-EDTA, washed with PBS, and resuspended in 1 mL of MACSQuant Running Buffer for cytometry (RB, Miltenyi Biotec Cat. 130-092-747). .. For the LV/CAR vector, non-permeabilized cells were stained by sequential incubation with biotinylated CD19 CAR Detection Reagent (Miltenyi Biotec Cat. 130-129-550) and anti-biotin-PE antibody (Miltenyi Biotec Cat. 130-113-291). .. Samples were acquired on a MACSQuant 10 flow cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany).



    Similar Products

    96
    Miltenyi Biotec cd19 microbeads
    a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
    Cd19 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd19/CD19+MicroBeads%2C+mouse/bio_rxiv__64898__2026__10__12__756217-223-7-9
    Average 96 stars, based on 1 article reviews
    cd19 microbeads - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    93
    Addgene inc pslcar cd19 28z addgene 135991 pmx gfp p2a rnf166
    a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
    Pslcar Cd19 28z Addgene 135991 Pmx Gfp P2a Rnf166, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd19/pSLCAR-CD19-28z+(Plasmid+%23135991)/pm42906538-313-15-16
    Average 93 stars, based on 1 article reviews
    pslcar cd19 28z addgene 135991 pmx gfp p2a rnf166 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    90
    OriGene cd19 antibody clone oti3b10
    a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
    Cd19 Antibody Clone Oti3b10, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd19/CD19+Mouse+Monoclonal+Antibody/pm42898331-190-32-36
    Average 90 stars, based on 1 article reviews
    cd19 antibody clone oti3b10 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology apc conjugated anti mouse cd19
    a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
    Apc Conjugated Anti Mouse Cd19, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd19/APC+Anti-Mouse+CD19+Antibody/pm42881448-350-74-85
    Average 94 stars, based on 1 article reviews
    apc conjugated anti mouse cd19 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    ATCC cd19 human b cell precursor 428 leukemia line nalm6
    a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
    Cd19 Human B Cell Precursor 428 Leukemia Line Nalm6, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd19/NALM6%2C+clone+G5/pm42888846-174-1-36
    Average 96 stars, based on 1 article reviews
    cd19 human b cell precursor 428 leukemia line nalm6 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec cd19car fmc63 apc fmc63 derived human cd19 car 130 127 344 rea1297 miltenyi biotec
    a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
    Cd19car Fmc63 Apc Fmc63 Derived Human Cd19 Car 130 127 344 Rea1297 Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd19/CD19+CAR+FMC63+Idiotype+Antibody%2C+REAfinity/pm42876290-371-203-212
    Average 93 stars, based on 1 article reviews
    cd19car fmc63 apc fmc63 derived human cd19 car 130 127 344 rea1297 miltenyi biotec - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd19 antibody conjugated magnetic beads
    a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
    Cd19 Antibody Conjugated Magnetic Beads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd19/CD19+MicroBeads%2C+human/pm42862270-70-15-19
    Average 96 stars, based on 1 article reviews
    cd19 antibody conjugated magnetic beads - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    93
    Proteintech cd19
    a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
    Cd19, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd19/CD19+Antibody/pm42860661-40-10-11
    Average 93 stars, based on 1 article reviews
    cd19 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd14 magnetic beads
    a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
    Cd14 Magnetic Beads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd19/CD19+MicroBeads%2C+human/pm42848521-152-9-12
    Average 96 stars, based on 1 article reviews
    cd14 magnetic beads - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Journal: bioRxiv

    Article Title: Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures

    doi: 10.64898/2026.10.12.756217

    Figure Lengend Snippet: a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Article Snippet: CD19+ B cells were positively selected using CD19 microbeads (Miltenyi Biotec, 130-121-301) following the manufacturer’s protocol.

    Techniques: Xenograft Assay, Immune Cell

    a, H&E staining of tumor sections from combination treatment groups. b, Multiplex immunofluorescence staining for CD3, CD19, CD23, and CD31 on tumor sections from the combination treatment group. c, Multiplex immunofluorescence staining for CD138, IgG and IgA on tumor sections from vehicle and combination treatment groups. d, Quantification of the CD138+ cell / mm 2 and IgG/IgA ratio in tumor sections from vehicle, single-agent, and combination treatment groups. n = 3 per group. e, UMAP plots of B cells at indicated time points post-treatment. f, BCR repertoire diversity, clonal dynamics, and SHM following combination treatment. g, Immunoglobulin isotype distribution of B cells over the treatment time course. h, Peripheral BCR repertoire diversity and SHM following combination treatment. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Journal: bioRxiv

    Article Title: Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures

    doi: 10.64898/2026.10.12.756217

    Figure Lengend Snippet: a, H&E staining of tumor sections from combination treatment groups. b, Multiplex immunofluorescence staining for CD3, CD19, CD23, and CD31 on tumor sections from the combination treatment group. c, Multiplex immunofluorescence staining for CD138, IgG and IgA on tumor sections from vehicle and combination treatment groups. d, Quantification of the CD138+ cell / mm 2 and IgG/IgA ratio in tumor sections from vehicle, single-agent, and combination treatment groups. n = 3 per group. e, UMAP plots of B cells at indicated time points post-treatment. f, BCR repertoire diversity, clonal dynamics, and SHM following combination treatment. g, Immunoglobulin isotype distribution of B cells over the treatment time course. h, Peripheral BCR repertoire diversity and SHM following combination treatment. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Article Snippet: CD19+ B cells were positively selected using CD19 microbeads (Miltenyi Biotec, 130-121-301) following the manufacturer’s protocol.

    Techniques: Staining, Multiplex Assay, Immunofluorescence

    a, Experimental schematic of the in vivo depletion and adoptive transfer study design. b, Tumor growth curves of mice treated with the combination regimen following depletion of B cells, CD4+ T cells, CD8+ T cells, NK cells, or FcyR blockade. n = 5-8 mice per group. c, Multiplex immunofluorescence staining for C3d, IgG, and CK8/18 on tumor sections from vehicle, single-agent, and combination treatment groups. n = 3 per group. d, Quantification of memory B cells in the spleen and tumor-draining lymph nodes from vehicle and combination treatment groups by flow cytometry. n = 4 per group. e, Quantification of long-lived plasma cells in the bone marrow from vehicle and combination treatment groups by flow cytometry. n = 5 per group. f, Serum levels of tumor-specific antibodies measured by flow cytometry in vehicle and combination treatment groups. n = 3-5 per group. g, (Left) Quantification of plasma cells generated from CD19+ splenocytes stimulated with tumor antigens in vitro. (Right) IgG binding to tumor cells detected by flow cytometry after incubation with culture supernatants from vehicle or combination treatment groups. h, Tumor volume curves of naive recipient mice receiving adoptive transfer of B cells or T cells from vehicle- or combination-treated donor mice, followed by tumor inoculation and half-dose RMC-6236 administration. n = 7 mice per group. i, Rechallenge tumor growth in non-CR and treatment-naive mice. n = 8 mice per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Journal: bioRxiv

    Article Title: Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures

    doi: 10.64898/2026.10.12.756217

    Figure Lengend Snippet: a, Experimental schematic of the in vivo depletion and adoptive transfer study design. b, Tumor growth curves of mice treated with the combination regimen following depletion of B cells, CD4+ T cells, CD8+ T cells, NK cells, or FcyR blockade. n = 5-8 mice per group. c, Multiplex immunofluorescence staining for C3d, IgG, and CK8/18 on tumor sections from vehicle, single-agent, and combination treatment groups. n = 3 per group. d, Quantification of memory B cells in the spleen and tumor-draining lymph nodes from vehicle and combination treatment groups by flow cytometry. n = 4 per group. e, Quantification of long-lived plasma cells in the bone marrow from vehicle and combination treatment groups by flow cytometry. n = 5 per group. f, Serum levels of tumor-specific antibodies measured by flow cytometry in vehicle and combination treatment groups. n = 3-5 per group. g, (Left) Quantification of plasma cells generated from CD19+ splenocytes stimulated with tumor antigens in vitro. (Right) IgG binding to tumor cells detected by flow cytometry after incubation with culture supernatants from vehicle or combination treatment groups. h, Tumor volume curves of naive recipient mice receiving adoptive transfer of B cells or T cells from vehicle- or combination-treated donor mice, followed by tumor inoculation and half-dose RMC-6236 administration. n = 7 mice per group. i, Rechallenge tumor growth in non-CR and treatment-naive mice. n = 8 mice per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Article Snippet: CD19+ B cells were positively selected using CD19 microbeads (Miltenyi Biotec, 130-121-301) following the manufacturer’s protocol.

    Techniques: In Vivo, Adoptive Transfer Assay, Multiplex Assay, Immunofluorescence, Staining, Flow Cytometry, Clinical Proteomics, Generated, In Vitro, Binding Assay, Incubation